(Boursier.com) – After that of Pfizer, it is the turn this Thursday of the antiviral pill Covid-19 molnupiravir of the American Merck gain approval from U.S. FDA regulators, offering high-risk patients another home treatment option as virus cases increase rapidly with the Omicron variant. However, the effectiveness of the treatment would be much lower than that of Pfizer’s product, Paxlovid. In both cases, this is an emergency use authorization from the US Food & Drug Administration.
© 2021 Boursier.com